CUE vs ESS · rev $9.3M vs P/E 31, rev $1.89B
Cue Biopharma (CUE) versus Essex Property Trust Inc (ESS) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Essex Property Trust Inc (ESS) is a reit - residential company listed on NYSE.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported ESS revenue for 2025-12-31 was $1.89B. Net income was $702.8M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
CUE currently screens at market cap $59.5M. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
Not investment advice. Open the CUE and ESS stock pages for the full models.
Not investment advice.